Dormancy models for mycobacterium tuberculosis: A minireview

Brazilian Journal of Microbiology

Volumn 46, Issue 3, 2015, Pages 641-647

  Alnimr, Amani M ^a  

^a IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY   (Saudi Arabia)

Author keywords

Dormancy; Latency; Stationary phase; Tuberculosis

Indexed keywords

ANIMALIA; BACTERIA (MICROORGANISMS); MYCOBACTERIUM TUBERCULOSIS;

DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; OXAZINE DERIVATIVE; RESAZURIN; TUBERCULOSTATIC AGENT; XANTHENE DERIVATIVE;

ANIMAL; ANTIBIOTIC RESISTANCE; DISEASE MODEL; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; GUINEA PIG; LATENT TUBERCULOSIS; MACACA FASCICULARIS; METABOLISM; MICROBIOLOGY; MOUSE; MYCOBACTERIUM TUBERCULOSIS; PATHOLOGY; RABBIT; TUBERCULOSIS, PULMONARY; ZEBRA FISH;

ANIMALS; ANTITUBERCULAR AGENTS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, BACTERIAL; GUINEA PIGS; INDICATORS AND REAGENTS; LATENT TUBERCULOSIS; MACACA FASCICULARIS; MICE; MYCOBACTERIUM TUBERCULOSIS; OXAZINES; RABBITS; TUBERCULOSIS, PULMONARY; XANTHENES; ZEBRAFISH;

EID: 84939555129     PISSN: 15178382     EISSN: 16784405     Source Type: Journal    
DOI: 10.1590/S1517-838246320140507     Document Type: Review

References (39)

1. Al-Sayyed B, Piperdi S, Yuan X et al. (2007) Monoclonal antibodies to Mycobacterium tuberculosis CDC 1551 reveal subcellular localization of MPT51. Tuberculosis (Edinb) 87:489-497.
2. Betts JC, Lukey PT, Robb LC et al. (2002) Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol Microbiol 43:717-731.
3. Broussard GW, Ennis DG (2007) Mycobacterium marinum produces long-term chronic infections in medaka: a new animal model for studying human tuberculosis. Comp Biochem Physiol C Toxicol Pharmacol 145:45-54.
4. Cho SH, Warit S, Wan B et al. (2007) Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother 51:1380-1385.
5. Comstock GW, Baum C, Snider DEJR (1979) Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies. Am Rev Respir Dis 119:827-830.
6. Cosma CL, Sherman DR, Ramakrishnan L (2003) The secret lives of the pathogenic mycobacteria. Annu Rev Microbiol 57:641-676.
7. Dickinson J, Mitchison D (1966) In vitro studies on the choice of drugs for intermittent chemotherapy of tuberculosis. Tuberculosis 47:370-380.
8. Dickinson JM, Mitchison DA (1970) Observations in vitro on the suitability of pyrazinamide for intermittent chemotherapy of tuberculosis. Tubercle 51:389-396.
9. Elwood RL, Wilson S, Blanco JC et al. (2007) The American cotton rat: a novel model for pulmonary tuberculosis. Tuberculosis (Edinb) 87:145-154.
10. Flynn JL (2006) Lessons from experimental Mycobacterium tuberculosis infections. Microbes Infect 8:1179-1188.
11. Gillespie SH (2002) Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective. Antimicrob Agents Chemother 46:267-274.
12. Ginsberg AM, Spigelman M (2007) Challenges in tuberculosis drug research and development. Nat Med 13:290-294.
13. Glaziou P, Falzon D, Floyd K et al. (2013) Global epidemiology of tuberculosis. Semin Respir Crit Care Med 34:3-16.
14. Grosset J (1980) Bacteriologic basis of short-course chemotherapy for tuberculosis. Clin Chest Med 1:231-241.
15. Hu Y, Coates A (2003a) Dormancy and Low Growth States in Microbial Disease, Cambridge University Press.
16. Hu Y, Coates AR, Mitchison DA (2003b) Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob Agents Chemother 47:653-657.
17. Hu Y, Coates AR, Mitchison DA (2006) Sterilising action of pyrazinamide in models of dormant and rifampicin-tolerant Mycobacterium tuberculosis. Int J Tuberc Lung Dis 10:317-322.
18. Hu Y, Coates AR, Mitchison DA (2008) Comparison of the sterilising activities of the nitroimidazopyran PA-824 and moxifloxacin against persisting Mycobacterium tuberculosis. Int J Tuberc Lung Dis 12:69-73.
19. Hu Y, Mangan JA, Dhillon, J et al. (2000) Detection of mRNA transcripts and active transcription in persistent Mycobacterium tuberculosis induced by exposure to rifampin or pyrazinamide. J Bacteriol 182:6358-6365.
20. James BW, Bacon J, Hampshire T et al. (2002) In vitro gene expression dissected: chemostat surgery for mycobacterium tuberculosis. Comp Funct Genomics 3:345-347.
21. Kell DB, Young M (2000) Bacterial dormancy and culturability: the role of autocrine growth factors. Curr Opin Microbiol 3:238-243.
22. Khan A, Sarkar D (2008) A simple whole cell based high throughput screening protocol using Mycobacterium bovis BCG for inhibitors against dormant and active tubercle bacilli. J Microbiol Methods 73:62-68.
23. Klinkenberg LG, Sutherland LA, Bishai WR et al. (2008) Metronidazole lacks activity against Mycobacterium tuberculosis in an in vivo hypoxic granuloma model of latency. J Infect Dis 198:275-283.
24. Loebel RO, Shorr E, Richardson HB (1933) The Influence of Foodstuffs upon the Respiratory Metabolism and Growth of Human Tubercle Bacilli. J Bacteriol 26:139-166.
25. McCune RM, Feldmann FM, McDermottW(1966) Microbial persistence. II. Characteristics of the sterile state of tubercle bacilli. J Exp Med 123:469-486.
26. Mccune RM JR, Mcdermott W, Tompsett R (1956) The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. II. The conversion of tuberculous infection to the latent state by the administration of pyrazinamide and a companion drug. J Exp Med 104:763-802.
27. Parrish NM, Dick JD, Bishai WR (1998) Mechanisms of latency in Mycobacterium tuberculosis. Trends Microbiol 6:107-112.
28. Puissegur MP, Botanch C, Duteyrat JL et al. (2004) An in vitro dual model of mycobacterial granulomas to investigate the molecular interactions between mycobacteria and human host cells. Cell Microbiol 6:423-433.
29. Saini DK, Tyagi JS (2005) High-throughput microplate phosphorylation assays based on DevR-DevS/Rv2027c 2-component signal transduction pathway to screen for novel antitubercular compounds. J Biomol Screen 10:215-224.
30. Sever JL, Youmans GP (1957) Enumeration of viable tubercle bacilli from the organs of nonimmunized and immunized mice. Am Rev Tuberc 76:616-635.
31. Stead WW, Kerby GR, Schlueter DP et al. (1968) The clinical spectrum of primary tuberculosis in adults. Confusion with reinfection in the pathogenesis of chronic tuberculosis. Ann Intern Med 68:731-745.
32. Stokes RW, Norris-Jones R, Brooks DE et al. (2004) The glycan-rich outer layer of the cell wall of Mycobacterium tuberculosis acts as an antiphagocytic capsule limiting the association of the bacterium with macrophages. Infect Immun 72:5676-5686.
33. Sugawara I, Yamada H, Mizuno S (2004) Pathological and immunological profiles of rat tuberculosis. Int J Exp Pathol85:125-134.
34. Swaim LE, Connolly LE, Volkman HE et al. (2006) Mycobacterium marinum infection of adult zebrafish causes caseating granulomatous tuberculosis and is moderated by adaptive immunity. Infect Immun 74:6108-6117.
35. Taneja NK, Tyagi JS (2007) Resazurin reduction assays for screening of anti-tubercular compounds against dormant and actively growing Mycobacterium tuberculosis, Mycobacterium bovis BCG and Mycobacterium smegmatis. J Antimicrob Chemother 60:288-293.
36. Tyagi S, Nuermberger E, Yoshimatsu T et al. (2005) Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob Agents Chemother 49:2289-2293.
37. Voskuil MI, Schnappinger D, Visconti KC et al. (2003) Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program. J Exp Med 198:705-713.
38. Wayne LG, Hayes LG (1996) An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun 64:2062-2069.
39. Wayne LG, Sohaskey CD (2001) Nonreplicating persistence of mycobacterium tuberculosis. Annu Rev Microbiol 55:139-163.